Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0KP9A
|
|||
| Former ID |
DNCL002306
|
|||
| Drug Name |
Anti-PD-L1
|
|||
| Synonyms |
BMS-936559
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Human immunodeficiency virus-1 infection [ICD-11: 1C62] | Phase 1 | [1] | |
| Solid tumour/cancer [ICD-11: 2A00-2F9Z] | Phase 1 | [1] | ||
| Company |
Bristol-Myers Squibb
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Programmed cell death 1 ligand 1 (PD-L1) | Target Info | . | [2] |
| KEGG Pathway | Cell adhesion molecules (CAMs) | |||
| Reactome | PD-1 signaling | |||
| WikiPathways | Costimulation by the CD28 family | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01455103) Phase 1 Biomarker Study of Anti-PDL-1 in Advanced Melanoma. U.S. National Institutes of Health. | |||
| REF 2 | Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012 Jun 28;366(26):2455-65. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.